PetVivo Reports Reports Fiscal 2024 Results

Fiscal 2024 Financial Highlights Fiscal 2024 Operational Highlights Management Commentary "Also during the year, we developed clinical data on the safety and efficacy of Spryng, increased distribution through the addition of Covetrusm, expanded our efforts with MWI, and increased market awareness of Spryng to veterinarians. "The release of tolerance clinical results involving the injection of Spryng into the joints of canines and felines have confirmed the long-known understanding that Spryng is a safe opti ...